Mundipharma
Hani Tak is a seasoned finance professional currently serving as the Commercial Finance Director for Rezzayo and BD at Mundipharma since August 2023. Previously, Hani held various roles at GSK from November 2011 to June 2023, including Manager of Pharma Supply Chain Deal Finance and Finance Partner within Global Support Functions. This role involved delivering financial management services that supported business goals. Hani also worked as a Finance Analyst in Corporate Development, focusing on strategic projects related to acquisitions and brand sales, and as an R&D Financial Analyst, providing technical accounting advice for R&D transactions. Earlier experience includes serving as Financial Controller at EUSA LLP, where responsibilities included ensuring compliance with IFRS, and as a Consultant at Ernst & Young. Hani holds an ACA degree from the Institute of Chartered Accountants of India.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.